Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB04725_nanopub.RA3jvzArnDl7LujF9NCIbLeBlOiw4_h3iSSS0bUHe4S-o#assertion>. }
Showing items 1 to 16 of
16
with 100 items per page.
- drugbank:DB04725 type drugbank_vocabulary:Drug assertion.
- drugbank:DB04725 label "Licofelone [drugbank:DB04725]" assertion.
- drugbank:DB04725 seeAlso DB04725 assertion.
- drugbank:DB04725 description "Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given." assertion.
- drugbank:DB04725 identifier "drugbank:DB04725" assertion.
- drugbank:DB04725 title "Licofelone" assertion.
- drugbank:DB04725 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:10243273 assertion.
- drugbank:DB04725 drugbank_vocabulary:x-pubchemcompound pubchem.compound:133021 assertion.
- drugbank:DB04725 drugbank_vocabulary:x-pdb pdb:LCF assertion.
- drugbank:DB04725 drugbank_vocabulary:x-chemspider chemspider:117391 assertion.
- drugbank:DB04725 drugbank_vocabulary:x-cas cas:156897-06-2 assertion.
- drugbank:DB04725 drugbank_vocabulary:drugbank-id "DB04725" assertion.
- drugbank:DB04725 bio2rdf_vocabulary:x-identifiers.org DB04725 assertion.
- drugbank:DB04725 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB04725" assertion.
- drugbank:DB04725 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB04725 bio2rdf_vocabulary:identifier "DB04725" assertion.